paclitaxel has been researched along with Inflammatory Breast Cancer in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (93.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Alpaugh, ML; Althufairi, BD; Chantarasriwong, O; Milcarek, AT; Morales, TH; Rezende, CO; Settle, AL; Theodoraki, MA; Theodorakis, EA | 1 |
| Alečković, M; Almendro, V; Clement, K; Egri, SB; Fassl, A; Frank, DA; Geck, RC; Harper, NW; Jaffe, JD; Jovanović, B; Kingston, NL; Li, Z; Long, HW; Meissner, A; Michor, F; Overmoyer, BA; Papanastasiou, M; Park, SY; Peluffo, G; Polyak, K; Pyke, AL; Qiu, X; Salas, J; Seehawer, M; Shu, S; Sicinski, P; Stevens, LE; Temko, D; Toker, A; Trinh, A; Walker, S; Wilde, CM; Zhou, N | 1 |
| Aitini, E; Bighin, C; Bisagni, G; Clavarezza, M; De Placido, S; Del Mastro, L; Durando, A; Galli, A; Garrone, O; Levaggi, A; Restuccia, E; Saracchini, S; Scalamogna, R; Turazza, M | 1 |
| Alvarez, RH; Andreopoulou, E; Cristofanilli, M; Fehn, K; Fineberg, S; Han, HS; Hershman, DL; Pellegrino, CM; Raptis, G; Sparano, JA; Vahdat, LT; Valero, V; Vigoda, IS; Wright, JJ | 1 |
| Aomatsu, N; Asano, Y; Hirakawa, K; Ishihara, S; Ishii, M; Ishikawa, T; Kashiwagi, S; Kawajiri, H; Kawakami, N; Mitsukawa, Y; Morisaki, T; Nakano, T; Noda, S; Onoda, N; Takashima, T; Watanabe, M | 1 |
| Barsky, SH; Boley, KM; Chu, K; Cristofanilli, M; Green, TL; Heise, C; Liu, H; Moraes, R; Robertson, FM; Wright, MC; Ye, Z; Zhang, X | 1 |
| D'Assoro, AB; Galanis, E; Gambino, MW; Goetz, MP; Iankov, I; Ingle, JN; Malatino, L; McCubrey, J; Opyrchal, M; Puccia, G; Salisbury, JL | 1 |
| Cai, R; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Bonev, V; Butler, J; Chen, JH; Evangelista, M; Hsiang, D; Lane, K; Mehta, R; Su, MY | 1 |
| Kumar, PV; Prabaharan, S; Ravind, R | 1 |
| Kawaguchi, H; Koga, C; Nakamura, Y; Nishimura, S; Nishiyama, K; Ohno, S; Shigematsu, H; Shiotani, S; Taguchi, K; Tanaka, K | 1 |
| Barnett, F; Harris, SJ; Seah, JA; White, SC | 1 |
| Benayoun, L; Bril, R; Gingis-Velitski, S; Kerbel, RS; Man, S; Milsom, C; Munster, M; Shaked, Y; Voloshin, T | 1 |
| Asuncion, D; Doroshow, JH; Forman, S; Frankel, P; Koczywas, M; Leong, L; Luu, T; Margolin, K; Morgan, R; Paz, IB; Pezner, R; Shibata, S; Somlo, G; Twardowski, P; VanderWalde, A; Wong, J; Ye, W | 1 |
| Bauerfeind, I; Burghardt, S; Ditsch, N; Hinke, A; Kahlert, S; Konecny, GE; Lenhard, M; Löhrs, B; Loibl, S; Toth, B; Untch, M; Vodermaier, A; Von Koch, F; VON Minckwitz, G | 1 |
5 trial(s) available for paclitaxel and Inflammatory Breast Cancer
| Article | Year |
|---|---|
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Farnesyl-Diphosphate Farnesyltransferase; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Quinolones; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2013 |
HER2 as a predictive factor for successful neoadjuvant anthracycline chemotherapy of locally advanced and early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Inflammatory Breast Neoplasms; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor, ErbB-2 | 2014 |
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Inflammatory Breast Neoplasms; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Thiotepa; Treatment Outcome | 2012 |
Dose-dense intensified sequential versus conventionally-dosed anthracycline and taxane-containing neoadjuvant therapy in patients with inflammatory breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Paclitaxel; Treatment Outcome | 2012 |
10 other study(ies) available for paclitaxel and Inflammatory Breast Cancer
| Article | Year |
|---|---|
Synthesis, structure-activity relationship and in vitro pharmacodynamics of A-ring modified caged xanthones in a preclinical model of inflammatory breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Inflammatory Breast Neoplasms; Molecular Structure; Structure-Activity Relationship; Xanthones | 2019 |
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Humans; Inflammatory Breast Neoplasms; Paclitaxel; Signal Transduction; STAT3 Transcription Factor; Stem Cells | 2023 |
[Case of a patient with inflammatory breast cancer who responded to preoperative chemotherapy with paclitaxel plus bevacizumab and could subsequently undergo surgery].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ductal, Breast; Female; Humans; Inflammatory Breast Neoplasms; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel | 2013 |
The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.
Topics: Animals; Apoptosis; Cell Line, Tumor; Depsipeptides; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Inflammatory Breast Neoplasms; Mice; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Spheroids, Cellular; Xenograft Model Antitumor Assays | 2013 |
Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Topics: Apoptosis; CD24 Antigen; Cell Line, Tumor; Chromosomal Instability; Cyclin-Dependent Kinase 2; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Hyaluronan Receptors; Imidazoles; Indoles; Inflammatory Breast Neoplasms; MCF-7 Cells; Neoplastic Stem Cells; Paclitaxel; Triple Negative Breast Neoplasms | 2014 |
Long-term follow-up of breast-conserving therapy in patients with inflammatory breast cancer treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Inflammatory Breast Neoplasms; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Trastuzumab; Treatment Outcome | 2014 |
Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Neoplasms, Second Primary; Paclitaxel; Prognosis; Quinazolines | 2016 |
A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Female; Humans; Inflammatory Breast Neoplasms; Lymphatic Metastasis; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2010 |
Inflammatory breast cancer and secondary Pure Red Cell Aplasia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Disease Progression; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Paclitaxel; Red-Cell Aplasia, Pure | 2011 |
G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist.
Topics: Animals; Antineoplastic Agents; Benzylamines; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclams; Drug Combinations; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Immunohistochemistry; Inflammatory Breast Neoplasms; Injections, Intraperitoneal; Matrix Metalloproteinase 2; Mice; Mice, Knockout; Neovascularization, Pathologic; Paclitaxel; Receptors, CXCR4; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |